GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Cash Flow from Financing

Novo Nordisk A/S (Novo Nordisk A/S) Cash Flow from Financing

: $-9,116 Mil (TTM As of Dec. 2023)
View and export this data going back to 1981. Start your Free Trial

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Novo Nordisk A/S paid $1,428 Mil more to buy back shares than it received from issuing new shares. It spent $52 Mil paying down its debt. It paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0 Mil from paying cash dividends to shareholders. It spent $0 Mil on other financial activities. In all, Novo Nordisk A/S spent $1,480 Mil on financial activities for the three months ended in Dec. 2023.


Novo Nordisk A/S Cash Flow from Financing Historical Data

The historical data trend for Novo Nordisk A/S's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,278.08 -5,272.59 -3,873.73 -7,375.44 -9,240.65

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,091.86 -2,966.11 -1,831.95 -2,838.13 -1,480.07

Novo Nordisk A/S Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Novo Nordisk A/S's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Novo Nordisk A/S's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9,116 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novo Nordisk A/S  (NYSE:NVO) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Novo Nordisk A/S's issuance of stock for the three months ended in Dec. 2023 was $0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Novo Nordisk A/S's repurchase of stock for the three months ended in Dec. 2023 was $-1,428 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Novo Nordisk A/S's net issuance of debt for the three months ended in Dec. 2023 was $-52 Mil. Novo Nordisk A/S spent $52 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Novo Nordisk A/S's net issuance of preferred for the three months ended in Dec. 2023 was $0 Mil. Novo Nordisk A/S paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Novo Nordisk A/S's cash flow for dividends for the three months ended in Dec. 2023 was $0 Mil. Novo Nordisk A/S received $0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Novo Nordisk A/S's other financing for the three months ended in Dec. 2023 was $-0 Mil. Novo Nordisk A/S spent $0 Mil on other financial activities.


Novo Nordisk A/S Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.